Angiotensin receptor/neprilysin inhibition with sacubitril/valsartan is an established therapy for heart failure (HF) with reduced ejection fraction, reducing cardiovascular death or HF hospitalizatio...

CONCLUSIONS: Elevated BMI was common and associated with greater hypertrophic, eccentric, and fibrotic remodeling in early-stage hypertrophic cardiomyopathy. Two-year increases in BMI were associated with greater phenotypic progression. These findings suggest prevention and treatment of elevated BMI may attenuate hypertrophic cardiomyopathy progression.

The widely used heart failure treatment sacubitril/valsartan has been linked to a lower risk of developing atrial fibrillation (AF) in people with heart failure with reduced ejection fraction (HFrEF), according to a large nationwide South Korean study. Sacubitril/valsartan was associated with a lower one-year risk of new-onset atrial fibrillation among patients with heart failure and reduced ...

We measured concentrations of 56 active pharmaceutical ingredients (APIs) in effluent samples from 50 large wastewater treatment plants across the US. Hydrochlorothiazide was found in every sample. Metoprolol, atenolol, and carbamazepine were found in over 90% of the samples. Valsartan had the highe …

Evidence remains limited on whether telmisartan with partial peroxisome proliferator-activated receptor-gamma (PPAR-γ) activity lowers new-onset diabetes mellitus (NODM) risk compared with non-PPAR-γ-active angiotensin II receptor blocker (ARB). We therefore evaluated the NODM risk of telmisartan compared with losartan, valsartan, and candesartan using real-world clinical data. We conducted a multicenter, retrospective, treatment-control cohort study using clinical data from 17 institutions between 2005 and 2023, covering 19 283 922 patients converted to a common data model. Adults newly prescribed telmisartan or other ARBs (losartan, valsartan, or candesartan) and taking the medication for ≥6 months were included, while patients with pre-existing diabetes were excluded. Propensity score matching (PSM) was performed, and hazard ratios (HR) were estimated using a Cox proportional hazards model. The primary outcome was incident NODM, defined by a diagnosis of diabetes (ICD-10), initiation of glucose-lowering medications, or HbA1c ≥ 6.5%. A total of 6 868 patients of new-users of telmisartan and 22 500 patients of other ARBs were included. In the overall population, telmisartan was associated with lower NODM risk (HR 0.87, 95% CI 0.80–0.94). After 1:2 PSM, there was no significant difference in the risk of NODM between telmisartan and other ARBs (10.61% [39.50/1 000 person-years] vs. 11.02% [40.42/1...

Journal of Human Hypertension - Comparison of telmisartan with losartan, valsartan, and candesartan on the risk of new-onset diabetes mellitus

The Sacubitril Valsartan Sodium Market is expected to grow from 1,940 USD Million in 2025 to 5 USD Billion by 2035. The Sacubitril Valsartan Sodium Market CAGR (growth rate) is expected to be around 9...